JPMorgan Chase & Co. decreased its position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 90.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 32,977 shares of the medical equipment provider's stock after selling 314,228 shares during the period. JPMorgan Chase & Co.'s holdings in Smith & Nephew were worth $1,027,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in shares of Smith & Nephew during the third quarter valued at approximately $792,000. Sanctuary Advisors LLC purchased a new position in Smith & Nephew during the second quarter valued at $627,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Smith & Nephew by 29.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 27,199 shares of the medical equipment provider's stock valued at $847,000 after buying an additional 6,164 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Smith & Nephew in the 3rd quarter worth about $1,258,000. Finally, Brandes Investment Partners LP increased its stake in shares of Smith & Nephew by 20.5% in the 2nd quarter. Brandes Investment Partners LP now owns 1,373,051 shares of the medical equipment provider's stock worth $34,002,000 after acquiring an additional 233,293 shares in the last quarter. Institutional investors own 25.64% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft cut shares of Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, November 1st. StockNews.com downgraded Smith & Nephew from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Finally, Berenberg Bank cut Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Wednesday, November 6th.
Read Our Latest Report on Smith & Nephew
Smith & Nephew Price Performance
NYSE:SNN traded up $0.10 on Friday, reaching $25.09. 452,949 shares of the stock traded hands, compared to its average volume of 858,115. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 12 month low of $23.65 and a 12 month high of $31.72. The company's fifty day simple moving average is $25.03 and its 200 day simple moving average is $27.73.
About Smith & Nephew
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Featured Articles
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
